Pd23-08 predictors of 5-Year Reoperation Rate After Transurethral Resection of the Prostate in a Diverse, Urban Academic Center

Abstract

men 45 to 80 years old with a prostate between 30cc and 80cc. WATER II (NCT03123250) is a prospective, multicenter, single-arm international clinical trial of Aquablation in men with a prostate between 80cc and 150cc. We compare 36-month outcomes amongst 116 WATER and 101 WATER II study subjects undergoing Aquablation. Students' t-test or Wilcoxon tests were used for continuous variables and Fisher's test for binary variables.RESULTS: International Prostate Symptom Score (IPSS) scores improved from 22.9 and 23.2 at baseline in WATER and WATER II, respectively, to 8.0 and 6.4 at 36 months, with 36-month reductions of 14.4 and 16.7 points, respectively (p[.07 for difference in change scores). At baseline, urinary flow rate (Qmax) was 9.4 and 8.7 cc/sec in WATER and WATER II, improving to 20.6 and 19.0 cc/sec, respectively (p[.70 for difference in change scores) at 36 months. Improvements in both IPSS and Qmax were immediate and sustained throughout follow-up. Change in IPSS, Qmax, and post-void residual (PVR) can be found in Figure 1.CONCLUSIONS: Aquablation clinically normalizes outcomes between patients with a 30cc to 80cc prostate and patients with an 80cc to 150cc prostate treated for LUTS/BPH. It is effective in patients with large prostate glands (>80cc) with acceptable complications out to three years. Source of Funding:The WATER and WATER II clinical trials are funded by PROCEPT BioRobotics. This abstract is submitted on behalf of all WATER and WATER II investigators